



Ceapro Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Live video webcast with President and CEO, Gilles Gagnon, on Wednesday, September 16th at 3:30 PM EDT

EDMONTON, Alberta, Sept. 14, 2020 -- [Ceapro Inc.](#) (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that [Gilles Gagnon, President and Chief Executive Officer](#) of Ceapro will present at the [H.C. Wainwright 22nd Annual Global Investment Conference](#) on Wednesday, September 16, 2020 at 3:30 PM EDT.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website [here](#).

A live [video webcast](#) of the presentation will be available on the [IR Calendar](#) page of the [Investors](#) section of the Company's website (www.ceapro.com). The video webcast replay will be made available two hours following the event and will be archived for 90 days.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Issuer:

Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release